Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 91 results:
Author Title Type [ Year] Filters: Keyword is Hypoglycemic Agents [Clear All Filters]
(2024).
Combination therapy with an SGLT-2 inhibitor and finerenone in DKD: Are we there yet?.
Eur J Clin Invest. 53(2), e13864.
(2023). Comparative efficacy of glucose-lowering drugs on liver steatosis as assessed by means of magnetic resonance imaging in patients with type 2 diabetes mellitus: systematic review and network meta-analysis..
Hormones (Athens). 22(4), 655-664.
(2023). Management of type 2 diabetes in the new era..
Hormones (Athens). 22(4), 677-684.
(2023). Peptide Polyagonists for the Treatment of Nonalcoholic Fatty Liver Disease..
Curr Pharm Des. 29(41), 3263-3265.
(2023). Socioeconomic aspects of incretin-based therapy..
Diabetologia. 66(10), 1859-1868.
(2023). Efficacy and safety of ultra-rapid insulin analogues in insulin pumps in patients with Type 1 Diabetes Mellitus: A systematic review and meta-analysis..
Diabetes Res Clin Pract. 193, 110144.
(2022). Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis..
Diabetologia. 65(8), 1251-1261.
(2022). Sotagliflozin for patients with type 2 diabetes: A systematic review and meta-analysis..
Diabetes Obes Metab. 24(1), 106-114.
(2022). Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes..
Ann Intern Med. 174(1), 141.
(2021). Comparative efficacy and safety of glucose-lowering drugs as adjunctive therapy for adults with type 1 diabetes: A systematic review and network meta-analysis..
Diabetes Obes Metab. 23(3), 822-831.
(2021). Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta-analysis..
Diabetes Obes Metab. 23(9), 2116-2124.
(2021). GLP-1 receptor agonists for cardiovascular outcomes with and without metformin. A systematic review and meta-analysis of cardiovascular outcomes trials..
Diabetes Res Clin Pract. 177, 108921.
(2021). Pharmacogenetics of the Glucagon-like Peptide-1 Receptor Agonist Liraglutide: A Step Towards Personalized Type 2 Diabetes Management..
Curr Pharm Des. 27(8), 1025-1034.
(2021). Ultra-rapid-acting insulins for adults with diabetes: A systematic review and meta-analysis..
Diabetes Obes Metab. 23(10), 2395-2401.
(2021). Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis..
Ann Intern Med. 173(4), 278-286.
(2020). Effect of exercise on key pharmacokinetic parameters related to metformin absorption in healthy humans: A pilot study..
Scand J Med Sci Sports. 30(5), 858-864.
(2020). Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors as combination therapy for type 2 diabetes: A systematic review and meta-analysis..
Diabetes Obes Metab. 22(10), 1857-1868.
(2020). In type 2 diabetes, SGLT2 inhibitors were linked to diabetic ketoacidosis vs. DPP-4 inhibitors..
Ann Intern Med. 173(12), JC70.
(2020). Some glucose-lowering drugs reduce risk for major adverse cardiac events..
Ann Intern Med. 173(2), JC9.
(2020). Diabetes in Menopause: Risks and Management..
Curr Vasc Pharmacol. 17(6), 556-563.
(2019). The effect of diabetes mellitus on in-hospital hyperglycemia, length of stay and survival in patients with brain tumor receiving dexamethasone: A descriptive and comparative analysis..
Clin Neurol Neurosurg. 184, 105450.
(2019). The effect of SGLT-2 inhibitors on albuminuria and proteinuria in diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials..
J Hypertens. 37(7), 1334-1343.
(2019). SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA..
Nephrol Dial Transplant. 34(2), 208-230.
(2019). SGLT-2 inhibitors in Diabetic Kidney Disease: What Lies Behind their Renoprotective Properties?.
Curr Med Chem. 26(29), 5564-5578.
(2019).